- The administration of oral hypoglycemic drugs is associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin
- Use with caution in patients with renal and hepatic impairment. If hypoglycemia occurs in such patients, appropriate management should be instituted
- Hypoglycemia is the most common adverse reaction of sulphonylurea therapy. Hypoglycemia is more likely to occur in elderly, debilitated patients when caloric intake is deficient, after severe or prolonged exercise, or when more than one glucose-lowering drug is used
- When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection or surgery, a loss of control may occur
- Patients with G6PD deficiency when treated with sulphonyl ureas may develop hemolytic jaundice
- Micronized formulations of glyburide are not bioequivalent with conventional formulations
- Monitor CrCl at baseline; blood and urine glucose periodically
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Severe cardiovascular disease
- Hypoglycemia
- Adrenal insufficiency
- Infection
- Stress
- Illness
- Change in diet or activity
- Changes in dose of other hypoglycemic medications
- Malnutrition
- G6PD deficiency
- Elderly patients
Pregnancy Category:C (conventional forms); B (micronized forms)
Breastfeeding: A decision should be made whether to discontinue nursing or to discontinue administering the drug, taking into account the importance of the drug to the mother. Limited data indicate that the levels of glyburide in breast milk are negligible. Monitoring of the breastfed infant's blood glucose is recommended. This information is based upon lactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 8 June 2010).
US Trade Name(s)
US Availability
glyburide (generic)
- TABS: 1, 1.25, 2.5, 3, 5, 6 mg
glyburide micronized (generic)
DiaBeta
Glynase (glyburide micronized)
Canadian Trade Name(s)
- Diabeta
- Med Glybe
- Mylan Glybe
Canadian Availability
glyburide (generic)
Diabeta
Med Glybe, Mylan Glybe
UK Trade Name(s)
UK Availability
Glibenclamide
Australian Trade Name(s)
Australian Availability
Daonil, Glimel
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- GlyBURIDE 2.5 MG TABS [Bottle] (COREPHARMA LLC)
30 mg = $16.99
90 mg = $42.97 - Glynase 6 MG TABS [Bottle] (PFIZER U.S.)
60 mg = $136.48
180 mg = $388.46 - GlyBURIDE 5 MG TABS [Bottle] (TEVA PHARMACEUTICALS USA)
30 mg = $18.99
60 mg = $29.98 - Diabeta 5 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
30 mg = $45.75
90 mg = $127.09 - Glynase 1.5 MG TABS [Bottle] (PFIZER U.S.)
60 mg = $56.68
180 mg = $155.35 - GlyBURIDE 1.25 MG TABS [Bottle] (TEVA PHARMACEUTICALS USA)
30 mg = $16.99
60 mg = $23.98 - Diabeta 1.25 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
50 mg = $29.99
100 mg = $49.97 - Glynase 3 MG TABS [Bottle] (PFIZER U.S.)
60 mg = $79.79
180 mg = $239.37 - Diabeta 2.5 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
30 mg = $29.99
60 mg = $57.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
